Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Similar documents
Ingredient Listing Qty. Unit NDC # Supplier

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)

Ingredient Listing Qty. Unit NDC # Supplier ml

Ingredient Listing Qty. Unit NDC # Supplier

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

Lidocaine Hydrochloride 2%, Metronidazole 2%, Misoprostol % Topical Ointment (Suspension, 30 g) Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier g

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

247 CMR BOARD OF REGISTRATION IN PHARMACY

905 UNIFORMITY OF DOSAGE UNITS

Student Practical Guide (1) Milk of Magnesia

Residual Solvents: FDA/ Regulatory Perspective

History Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.

13. SUPPOSITORY Suppository Bases. The active substance is prepared in a suitable bases. An ideal suppository bases should carry:

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

REVISION OF MONOGRAPH ON TABLETS. Tablets

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

The Pharmacy Board of Australia s

INTRODUCTION. Asthma Drug Delivery - 1

» Croscarmellose Sodium is a cross linked polymer of carboxymethylcellulose sodium.

The Therapeutic Goods Act (1989)

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

CATEGORY IV MONOGRAPH. Athlete's Foot Treatments

LABELLING STANDARD ANTIFUNGALS (TOPICAL)

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

KEYWAX WX1014 RUBBER WAX CONCENTRATE

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Food supplement manufacture

USP Chewable Gels Monographs

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS SULPHUR. FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1973

Model Standards for Pharmacy Compounding of Non-Sterile Preparations

SOFTISAN 100, 142, 154

DENTCA Denture Teeth - Directions for Use

SLEEP AIDS - LABELLING STANDARD

Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY

Safety Data Sheet. Product Name: DetectX Glutathione Colorimetric Detection Kit. Section 1: Identification. Section 2: Hazard(s) Identification

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. ZINEB Zinc ethylenebisdithiocarbamate

AgraQuant F.A.S.T. Casein Sandwich ELISA

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

NATURAL HEALTH PRODUCT FUNGAL PROTEASE

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

ANIMAL HEALTH DIVISION. Technologies & Services

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

A. General Appearance

AGP: CP/89 FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS. PHENTHOATE S - a - ethoxycarbonylbenzyl 00-dimethyl phosphorodithioate

Suppositories. Suppositories: 08/10/2016

Stability Study of Hydralazine HCl Oral Solutions Compounded in Humco Oral Vehicles to Determine a Beyond-use Date

MIGLYOL Gel B, Gel T, 840 Gel B

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. BROMOPHOS 4-bromo-2,5-dichloropheny1 dimethy1 phosphorothioate

Introduction to Compounding INTRODUCTION. L earning Objectives CHAPTER

Addendum to the 2016 FAO/WHO Manual on pesticide specifications: revised Tablet Specifications for DT, ST and WT

In partnership with: Cardinal Health Exam Gloves. When it comes to safety and comfort, we ve got you covered.

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

MATERIAL SAFETY DATA SHEET

Material Safety Data Sheet:

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

LABELLING FOR DISPENSED PRODUCTS

The Mechanics of the Dental Anesthetic Cartridge

Guidance for Pharmacists on Extemporaneous Dispensing

(12) Patent Application Publication (10) Pub. No.: US 2006/ A1

STANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS

Nappage/Cake glaze and spray glaze

Prescribing and Dispensing Drugs

FLAVOUR FLOW & ADHESION

ANTACID LABELLING STANDARD

Safety Data Sheet. Product Name: DetectX Palladium Screening Fluorescent Detection Kit. Section 1: Identification. Section 2: Hazard(s) Identification

THE NOTIFICATION OF MINISTRY OF PUBLIC HEALTH NO. 158 [B.E (1994)] Supplementary Food for Infants and Young Children

Application Bulletin. Nutritional Bars. Corn Products Specialty Ingredients products for use in this application:

INSTRUCTIONS FOR USE AND CARE

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA

Copyright 2017 PureGreens Nutrition Pte Ltd. All rights reserved. Published by Samuel Grenville.

MATERIAL SAFETY DATA SHEET

INTERNATIONAL STANDARD

NEPHROCHECK Calibration Verification Kit Package Insert

Easy, fast and reliable!

Inspection Report Item 29: Compliance with Variance, Specialized Process, Reduced Oxygen Packaging Criteria, and HACCP Plan

Vol. 41(1) [Jan. Feb. 2015] (P) \\uspnetapp2\share\share\uspnf\printq\pager\xmlin\lyc_ _m99989.xml. Nov.

AGP:CP/365,1998 SULFOMETURON METHYL. 2-(4,6-dimethylpyrimidin-2-ylcarbamoylsulfamoyl) benzoic acid, methyl ester

EMTRICITABINE AND TENOFOVIR TABLETS

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

Stability of Captopril in an Extemporaneously Compounded Humco s Oral Products

NEPHROCHECK Liquid Control Kit Package Insert

Recall Guidelines. for Chinese Medicine Products

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

March 4, 2017 Built for Speed

GLOBAL SPECIALTY INGREDIENTS (M) SDN BHD ( M)

Chapter 8. Nonsterile Pharmaceutical Compounding. Paradigm Publishing, Inc. 1

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

Transcription:

11/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Methimazole, USP 0.300 g Tuna Flavor 1.50 g Glycerin, USP** 6.0 ml Chew-A-Treat Compound A 22.80 g Chew-A-Treat Compound C 46.30 g **Note: Caprylic/Capric Triglyceride can be used to replace Glycerin to reduce stickiness. SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information Lot Number Expiry Date Light Sensitive (protect from light whenever possible): Hygroscopic (protect from moisture whenever possible): Methimazole Glycerin Preparatory Guidelines Non-Sterile Preparation Sterile Preparation Processing Error / Testing Considerations: Special Instruction: To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients. Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

11/23/2015; Page 2 SUGGESTED PREPARATION (for 60 x 1 ml Treats) Weigh and / or measure the following ingredients when appropriate: Ingredient Listing Qty. Unit Multiplication factor (*) : Processing Error Qty. to measure Methimazole, USP 0.300 g Tuna Flavor 1.50 g Glycerin, USP 6.0 ml Chew-A-Treat Compound A 22.80 g Chew-A-Treat Compound C 46.30 g * Takes into account increased batch size conversions and density conversions, if required. Weigh / measure just prior to use. 1. Mold lubrication: Preparatory Instruction A. Lubricate all parts of the Chew-A-Treat Mold with suitable vegetable spray and set aside. Note: Selected vegetable spray needs to be compatible with API(s) and all other ingredients within the formulation. 2. Powder preparation: A. Triturate the Chew-A-Treat Compound C to form a fine, homogeneous powder blend. B. Triturate the Methimazole to form a fine, homogeneous powder. C. By geometric addition, combine and mix the following ingredients together to form a homogeneous mixture: -Fine, homogeneous powder (Step 2B) -Fine, homogeneous powder blend (Step 2A) D. Transfer the mixture (Step 2C) to a beaker and incrementally add the Glycerin. Specifications: Continuously mix until homogeneous. End result: Homogeneous moist blend. Note: The mixture will have a sand-like texture. If it begins to stick to your stirring device or beaker, you can simply scrape it off and continue mixing.

11/23/2015; Page 3 3. Medium integration: A. Prepare a hot water bath to between 60 C and 65 C. B. Using the hot water bath, melt the Chew-A-Treat Compound A. Specifications: Continuously mix. Maintain temperature between 60 C and 65 C. End result: Homogeneous thick, sticky liquid-like dispersion. C. In the given order, sequentially add the following ingredients to the melted Chew-A-Treat Compound A (Step 3B): -Tuna Flavor -Homogeneous moist blend (Step 2D) Specifications: Continuously mix until homogeneous. Maintain temperature between 60 C and 65 C. End result: Homogeneous thick, sticky paste-like dispersion. Note: Add the next ingredient, once the previous one has been completely added and dispersed. 4. Mold filling: A. Properly lubricate gloves (thumbs, forefingers, and palms) throughout filling. B. Continuing to heat the mixture between 60 to 65 C, remove a marble-sized quantity of the mixture at a time and roll it between your thumb and forefinger to form a cylinder. Pack the 60 mold cavities with these cylinders and scrape off any excess with pre-lubricated plastic scraper. C. Once the treats have been packed down with an extractor, apply a thin layer of lubricant to give a shining surface. D. Allow the treats to cool at room temperature for at least 15 minutes and then remove them from the mold using the extractor. 5. Validation technique: A. Weigh 12 chewable treats. B. The final weight of each chewable treat (not including chewable treat mold) shall not be less than 90% and not more than 110% of the theoretically calculated weight for each unit (1.31 g), in accordance to USP guidelines.

11/23/2015; Page 4 6. Product transfer: Transfer the final product into the specified dispensing container (see Packaging Requirements ). SUGGESTED PRESENTATION Estimated 30 days, as per USP. Beyond-Use Date Packaging Requirements Manually put into light-resistant Chew-A-Treat blisters and cold seal with foil labels. 1 Use as directed. Do not exceed prescribed dose. 6 Keep in a dry place. Auxiliary Labels 2 Keep out of reach of children. 7 3 For Feline use only. 8 Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use. Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. 4 May impair mental or physical ability. 9 Keep at room temperature (20 C 23 C). 5 Protect from light. 10 Discard container after use. Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. Patient Instructions If allergic reactions occur, consult your pharmacist.

11/23/2015; Page 5 REFERENCES 1. Lozenges/Troches. In: Allen, LV, Jr. The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition. American Pharmaceutical Association; 2012: 183 2. Tapazole. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2015: 2896. 3. Glycerin. In: Rowe RC. Handbook of Pharmaceutical Excipients, 7 th Edition. American Pharmaceutical Association; 2012: 324. 4. Thiamazole. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36 th Edition. London, England: The Pharmaceutical Press; 2009: 2176. 5. Methimazole (Monograph). In: O Neil MJ. The Merck Index 15 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #6043. 6. Methimazole. In: Trissel LA. Trissel s Stability of Compounded tions, 5 th Edition. American Pharmaceutical Association; 2012: 316. 7. Methimazole. United States Pharmacopeia XXXVIII / National ry 33. Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 4311. 8. Methimazole. Thomson Micromedex. USP DI Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 453. 9. Methimazole. In: Plumb DC. Veterinary Drug Handbook 6 th edition. Pharmavet Publishing; 2008: 588. 10. USP <795>. United States Pharmacopeia XXXVIII / National ry 33. Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 559. DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.